Search results for: Rat Anti-Human IgM mu Chain Antibodies
#7868159 
//
To Up
Depletion of IgM xenoreactive natural antibodies by injection of anti-mu monoclonal antibodies.
It is believed that IgM xenoreactive natural antibodies (XNA) and activation of complement are the two main effectors involved in the hyperacute rejection (HAR) of discordant xenografts, such as pig-to-primate kidney, liver or heart transplants. We have hypothesized that long-term depletion of circulating IgM XNA might be able to overcome HAR and induce the "accommodation" of pig-to-primate vascular discordant xenografts. Several techniques have been described to eliminate circulating XNA in primates but, up to now, none has been able to totally deplete these antibodies for a sufficiently long period of time in order to test the hypothesis of discordant xenograft "accommodation". Previous reports from our laboratory have shown that, in rodents, B-cell immunosuppression could be achieved by neonatal administration of anti-mu antibodies. Recently we have shown that administration of an anti-mu mAb, in adult rats, was able to totally deplete circulating IgM and IgM XNA, without immune complex disease. Furthermore, we have used different methods such as splenectomy, plasma exchange and an anti-B cell immunosuppressive agent mycophenylate mophetil (RS61443, Syntex, Palo Alto, USA) to pre-deplete circulating IgM before administration of anti-mu mAb (MARM-7) and showed that the effectiveness of anti-mu mAb to deplete circulating IgM was increased by 100-fold. Depletion of circulating IgM in adult rats by anti-mu mAb (MARM-7) was used as an experimental model to study the role of IgM XNA in the pathogenesis of HAR in guinea pig-to-rat cardiac xenografts. Our data show that IgM XNA play a major role in HAR, even if in this discordant combination direct activation of complement, probably through the alternative pathway, seems to be the main effector involved in HAR. We have analyzed the mechanisms of anti-mu depletion of circulating IgM in adult animals and shown that, besides anti-mu/IgM immune complex formation, depletion of circulating IgM results from the very significant inhibition of B-cell differentiation and secretion of IgM following in vivo crosslinking and internalization of surface IgM on B cells. As well, we provide evidence demonstrating that anti-mu mAb blocks B cells at an early stage of maturation, probably in the bone marrow. Furthermore, we have developed several rat anti-human and anti-baboon IgM mAb and tested their ability to deplete circulating IgM and IgM XNA in baboons, after splenectomy or splenectomy and plasma exchange.(ABSTRACT TRUNCATED AT 400 WORDS)D Latinne, M Soares, X Havaux, F Cormont, B Lesnikoski, F H Bach, H Bazin
2449 related Products with: Depletion of IgM xenoreactive natural antibodies by injection of anti-mu monoclonal antibodies.
100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug
Related Pathways
#6114491 //
To Up
Presence of autoantibody for phospholipase inhibitory protein, lipomodulin, in patients with rheumatic diseases.
The activity of phospholipase inhibitory protein, lipomodulin, partially purified from rabbit neutrophils, was markedly decreased after treatment with sera from patients with rheumatic diseases such as systemic lupus erythematosus, rheumatoid arthritis, and dermatomyositis. The decrease of the protein's inhibitory activity on phospholipase A2 paralleled the amount of [35S]methionine-labeled lipomodulin precipitated by the sera. Absorption of patients' sera with anti-human IgM (mu chain) or protein A-agarose, but not with anti-human IgG (gamma chain), decreased their ability to decrease the activity of lipomodulin on phospholipase A2 or to precipitate the radioactive lipomodulin. The IgM fraction of patients' sera could precipitate [35S]methionine-labeled lipomodulin (40,000 daltons) which comigrated with highly purified lipomodulin on gel electrophoresis with sodium dodecyl sulfate. All of these observations suggest that the sera of many patients with rheumatic diseases contain autoantibody against lipomodulin. A monoclonal antibody against lipomodulin was also obtained. Stimulating human fibroblasts with bradykinin in the presence of monoclonal antilipomodulin antibody markedly enhanced arachidonic acid release due to the activation of phospholipase(s) in the intact cells, and this stimulatory effect was blocked by adding purified lipomodulin. These findings suggest that lipomodulin regulates the activity of phospholipase(s) on the cell surface and that autoantibodies against lipomodulin may play a role in certain symptoms of rheumatic diseases, especially by the formation of prostaglandins and other metabolites of arachidonic acid.F Hirata, R del Carmine, C A Nelson, J Axelrod, E Schiffmann, A Warabi, A L De Blas, M Nirenberg, V Manganiello, M Vaughan, S Kumagai, I Green, J L Decker, A D Steinberg
1557 related Products with: Presence of autoantibody for phospholipase inhibitory protein, lipomodulin, in patients with rheumatic diseases.
1 Set1 Set1 Set1 Set100ug Lyophilized1 Set1 Set1 Set1 Set100 μg100ug Lyophilized1 Set
Related Pathways
#823261 //
To Up
Isolation of rat and rabbit IgM from normal serum using anti-human mu antibody-polyacrylamide beads immunosorbents.
The antigenic relationship between human IgM and IgM from other species has been utilized in isolating rat and rabbit IgM from normal sera by means of an anti-human mu-polyacrylamide beads immunoadsorbent. The isolated IgM was found to be pure by immunoelectrophoretic analysis and Ouchterlony technique. The antisera obtained were monospecific for mu-chains after absorption with IgG. Lastly, the IgM isolated always retained its antibody activity.C Sapin, P Druet